ICE (Ifosfamide + Carboplatin + Etoposide), 3 cycles

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-IFOSFAMIDE` `DRUG-CARBOPLATIN` `DRUG-ETOPOSIDE`

ID	`REG-ICE`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-BCELL-2025`

Notes

STUB. Salvage / pre-transplant cytoreduction. Hemorrhagic cystitis risk without mesna is fatal; ifosfamide encephalopathy — methylene blue treatable. Used in HSTCL induction + DLBCL R/R + Hodgkin salvage.

Used By

Indication

IND-EATL-2L-ICE - IND-EATL-2L-ICE
IND-HSTCL-1L-ICE-ALLOSCT - IND-HSTCL-1L-ICE-ALLOSCT